

Edgar Filing: GERON CORP - Form 8-K

GERON CORP  
Form 8-K  
April 03, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 2, 2007

GERON CORPORATION  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-20859 (Commission File Number)	75-2287752 (IRS Employer Identification No.)
--	-------------------------------------	--

230 CONSTITUTION DRIVE  
MENLO PARK, CALIFORNIA 94025  
(Address of principal executive offices, including zip code)

(650) 473-7700  
(Registrant's telephone number, including area code)

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On April 2, 2007, the United States Patent and Trademark Office (USPTO) issued first actions in the reexamination proceedings of three U.S. patents covering human embryonic stem cells. The patents - U.S. Patent Nos. 5,843,780,

Edgar Filing: GERON CORP - Form 8-K

6,200,806 and 7,029,913 - are assigned to the Wisconsin Alumni Research Foundation (WARF) and are licensed to Geron pursuant to a January 2002 license agreement. In the first USPTO actions, all claims of the three patents were rejected as unpatentable. The next stage in the reexamination proceedings will be the filing of a response by WARF. The reexaminations were requested by the Foundation for Taxpayer and Consumer Rights and the Public Patent Foundation.

The Company's Press Release, dated April 2, 2007, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

- Item 9.01 Financial Statements and Exhibits.
- (a) Financial Statements of Businesses Acquired.  
None.
  - (b) Pro Forma Financial Information.  
None.
  - (c) Shell Company Transactions.  
None.
  - (d) Exhibits.  
99.1 Press Release dated April 2, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: April 3, 2007

By: /s/ David L. Greenwood  
-----  
David L. Greenwood  
Executive Vice President and  
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated April 2, 2007.